Karo Bio's cholesterol drug enters PK studies
Swedish drugmaker Karo Bio says that KB2115, its drug candidate for severe dyslipidemia, has received approval from the Swedish Medical Products Agency for a two-week bioavailability study in healthy volunteers.
In a previous clinical study, Karo Bio showed that KB2115 significantly lowers harmful cholesterol up to 40% in a two-week period and exhibited a safety profile that is satisfactory for further development.
The firm noted that its new formulation is suitable for daily dosing in patients in the continued clinical development of KB2115. The study, which Karo Bio will initiate during the spring will, determine the agent's pharmacokinetic properties in preparation for a Phase II program in patients which is planned for the fall.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze